GENITOURINARY CANCERS

A comprehensive review of the efficacy and safety data from the phase 3 CLEAR trial (Study 307/KEYNOTE-581) for the frontline treatment of advanced renal cell carcinoma.

An expert in genitourinary oncology, Robert J. Motzer, MD, reviews the recent historic advances in frontline combinations for the treatment of advanced clear-cell renal cell carcinoma.

The novel, selective hypoxia-inducible factor-2 alpha inhibitor belzutifan was granted a priority review by the FDA for the treatment of patients with von Hippel-Lindau disease–associated renal cell carcinoma who do not require immediate surgery.

The first therapy for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies has been granted approval by the FDA.

During a virtual Targeted Oncology Case-Based Roundtable, Manojkumar Bupathi, MD, MS, reviewed second-line treatment options for transitional cell carcinoma.

During a virtual Targeted Oncology Case-Based Roundtable event, Anish B. Parikh, MD, discussed front-line treatment options for metastatic urothelial cancer as well as the data supporting avelumab maintenance.

The FDA has granted an Orphan Drug Designation to Padeliporfin Immune Photo Activated Cancer Therapy for the treatment of adult patients with upper tract urothelial cancer.

Updated data show a continued survival benefit for patients with metastatic renal cell carcinoma as the group reached the median overall survival endpoint for the phase II MERECA study.

During a Targeted Oncology Case-Based Peer Perspective virtual event, Amir Mortazavi, MD andMoshe Ornstein, MD, MA discussed available treatment regimen for a patient with clear cell renal cell carcinoma and sarcomatoid features.

Treatment with lanreotide autogel in patients with pancreatic neuroendocrine tumors, and midgut neuroendocrine tumors did not cause deterioration in quality-of-life, according to new data from the Phase II CLARINET FORTE study.

A promising efficacy signal was observed when the immune checkpoint inhibitor durvalumab was added concurrently to radiation followed by adjuvant durvalumab as treatment of patients with localized urothelial bladder cancer.

The National Comprehensive Cancer Network released the first set of guidelines for pediatric patients with nephroblastoma for oncologists and primary care physicians.

In an interview with Targeted Oncology, Shaakir Hasan, DO, discussed the results found when diagnostic and treatment information from patients with bladder cancer was prospectively assessed. He also discussed future work on disparities in health care in an interview with Targeted Oncology.

The durvalumab indication as a treatment for previously treated adult patients with locally advanced or metastatic bladder cancer has been voluntarily withdrawn in the United States by AstraZeneca, the developer of the PD-L1 inhibitor, the company announced in a press release.

The submission of 2 Biologic License Applications for enfortumab vedotin-ejfv have been made to the FDA for consideration as treatment of patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and who are ineligible for cisplatin.

The FDA has accepted a Biologic License Application for Vicineum as a treatment option for patients with high-risk, Bacillus Calmette-Guerin-unresponsive non–muscle invasive bladder cancer, and granted it Priority Review,.

Findings from the phase 3 CLEAR trial showed that the addition of lenvatinib to either pembrolizumab or everolimus led to an improvement in survival and response rates in comparison with sunitinib monotherapy in the first-line setting for patients with advanced renal cell carcinoma.

The addition of the oral hypoxia-inducible factor 2α inhibitor belzutifan to cabozantinib led to disease control in a majority of patients with previously treated advanced clear cell renal cell carcinoma, according to preliminary results from a phase 2 trial presented at the 2021 Genitourinary Cancers Symposium.

Cabozantinib reduced the risk of disease progression or death by 40% in comparison with sunitinib in patients with metastatic papillary renal cell carcinoma, according to findings from the randomized phase 2 SWOG 1500 study.

A molecular signature has been identified that can characterize long-term responders from treatment with apalutamide and androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer, according to findings, presented at the 2021 Genitourinary Cancers Symposium.

In patients with non-muscle invasive bladder cancer carcinoma in-situ who were unresponsive to Bacillus Calmette-Guerin, the addition of N-803 induced a high rate of complete responses, findings from a cohort of the phase 2/3 QUILT-3.032 study showed.

Localized metastatic lesions were detected with a high correct localization rate (CLR) and positive predictive value (PPV) with the investigational prostate-specific membrane antigen (PSMA)–targeted PET imaging agent 18F-DCFPyL.

Patrick G. Pilié, MD, explains how the safety profile of darolutamide, as seen in the ARAMIS clinical trial, differs from those of enzalutamide and apalutamide.

Apalutamide in combination with androgen deprivation therapy led to a reduction in the risk of death of 35% in comparison with ADT alone for patients with metastatic castration-sensitive prostate cancer in a final analysis of the phase 3 TITAN trial.

Enfortumab vedotin demonstrated superior efficacy compared with chemotherapy in patients with advanced urothelial carcinoma who had previously received platinum-based chemotherapy and PD-1/L1 inhibition, according to results from a primary analysis of the phase 3 EV-301 clinical trial.

Nivolumab in combination with cabozantinib continues to demonstrate superior efficacy over sunitinib monotherapy in the frontline treatment of patients with advanced renal cell carcinoma, according to extended follow-up data from the phase 3 CheckMate 9ER trial.

A novel prostate-specific membrane antigen–targeted radiopharmaceutical for positron emission tomography known as 18F-DCFPyL, may help to identify occult prostate cancer and more accurately characterize disease burden, according to a subanalysis of the OSPREY trial presented during the 2021 Genitourinary Cancers Symposium.

In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), crossover from placebo to darolutamide (Nubeqa) appeared have minimal impact on the overall survival (OS) benefit observed with the androgen receptor inhibitor in the pivotal phase 3 ARAMIS trial.

During a Targeted Oncology Case-Based Peer Perspectives Roundtable, Tanya Dorff, MD, reviews the available treatment options for nonmetastatic castration-resistant prostate cancer to select a treatment for 57-year-old patient.

An exploratory analysis of the phase 3 IMvigor130 trial demonstrated that the benefit of frontline atezolizumab added to gemcitabine and platinum chemotherapy was maintained in patients with urothelial cancer, regardless of the site of the primary tumor.